Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up After Analyst Upgrade

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price gapped up prior to trading on Friday after Raymond James raised their price target on the stock from $51.00 to $56.00. The stock had previously closed at $29.90, but opened at $32.25. Raymond James currently has an outperform rating on the stock. Dianthus Therapeutics shares last traded at $30.56, with a volume of 27,707 shares trading hands.

Several other analysts have also weighed in on the company. Wedbush lowered their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Robert W. Baird assumed coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Oppenheimer assumed coverage on Dianthus Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 price objective for the company. Finally, Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $45.86.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Quest Partners LLC grew its holdings in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after buying an additional 4,506 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $236,000. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Dianthus Therapeutics by 281.9% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock worth $1,022,000 after buying an additional 29,159 shares during the period. Finally, Point72 DIFC Ltd acquired a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $334,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Down 2.8 %

The company has a 50-day moving average price of $27.75 and a 200-day moving average price of $26.51. The firm has a market capitalization of $853.49 million, a price-to-earnings ratio of -5.25 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -2.28 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.